Long-term safety and tolerability of delamanid-containing regimens in MDR- and XDR-TB patients in a specialised tuberculosis treatment center in Berlin, Germany

Eur Respir J. 2020 Jul 6:2000009. doi: 10.1183/13993003.00009-2020. Online ahead of print.

Authors

Brit Häcker^{1

2}, Nicolas Schönfeld^{3

2}, David Krieger³, Ralf Otto-Knapp^{2

4}, Norbert Hittel⁵, Patricia Pflugmacher³, Torsten Bauer^{3

2}

Affiliations

¹ Klinik für Pneumologie, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany bhaecker@dzk-tuberkulose.de.
² DZK - German Central Committee against tuberculosis (DZK e.V.), Berlin, Germany.
³ Klinik für Pneumologie, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany.
⁴ MVZ PneumoCare, Berlin, Germany.
⁵ Otsuka Novel Products GmbH, Munich, Germany.

PMID: 32631834
DOI: 10.1183/13993003.00009-2020

No abstract available

Publication types

Letter